Related Experiment Video
Updated: Mar 21, 2026
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.9K
Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and Myeloma Pathophysiology
1Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02215, USA.
Cancer Cell
|May 12, 2016
Abstract:
In this issue of Cancer Cell, Zhang et al. report that TJP1 suppresses EGFR/JAK1/STAT3-mediated signaling and increases the proteasome inhibitor sensitivity of myeloma cells by altering the cellular proteasome capacity versus proteasome load of undegraded intracellular proteins.
Insights
Tight junction protein 1 (TJP1) suppresses EGFR/JAK1/STAT3 signaling in myeloma cells. This finding enhances sensitivity to proteasome inhibitors by modulating cellular proteasome capacity and protein degradation.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Multiple myeloma is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
- Epidermal growth factor receptor (EGFR) and JAK/STAT signaling pathways are implicated in myeloma pathogenesis.
- Proteasome inhibitors are a cornerstone of multiple myeloma therapy, but drug resistance remains a challenge.
Purpose of the Study:
- To investigate the role of Tight Junction Protein 1 (TJP1) in multiple myeloma.
- To determine the effect of TJP1 on EGFR/JAK1/STAT3 signaling in myeloma cells.
- To assess the impact of TJP1 on the sensitivity of myeloma cells to proteasome inhibitors.
Main Methods:
- Utilized molecular biology techniques to analyze TJP1 expression in myeloma cells.
- Investigated the interaction between TJP1 and the EGFR/JAK1/STAT3 signaling pathway.
- Assessed the effect of TJP1 modulation on proteasome activity and myeloma cell response to proteasome inhibitors.
Main Results:
- TJP1 was found to suppress EGFR/JAK1/STAT3-mediated signaling in myeloma cells.
- TJP1 alters the balance between cellular proteasome capacity and the load of undegraded proteins.
- Overexpression or modulation of TJP1 increased the sensitivity of myeloma cells to proteasome inhibitors.
Conclusions:
- TJP1 acts as a suppressor of oncogenic signaling pathways in multiple myeloma.
- TJP1 influences proteasome homeostasis, impacting drug response.
- Targeting TJP1 or related pathways may represent a novel therapeutic strategy to overcome proteasome inhibitor resistance in multiple myeloma.
Related Concept Videos
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
02:23Abnormal Proliferation
5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
01:31The Intrinsic Apoptotic Pathway
9.1K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.1K
01:29Tight Junctions
8.6K
Tight junctions are molecular seals between cells that prevent the leaking of fluids, ions, and other small solutes across cavities and compartments in multicellular organisms. They are mainly composed of claudin and occludin transmembrane proteins, and other proteins such as tricellulin and JAM (junctional adhesion molecule). All these proteins are 4-pass transmembrane proteins, except JAM, which is a single-pass transmembrane protein belonging to the immunoglobulin superfamily. The...
8.6K
02:18The Proteasome
10.5K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.5K